HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
about
Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumabBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsNon-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsRole of HER2 in NSCLCAnalysis of different HER-2 mutations in breast cancer progression and drug resistanceIs there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?Correlation of human epidermal growth factor receptor protein expression and colorectal cancerPredictive biomarkers in precision medicine and drug development against lung cancerHER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approachesNormal morphogenesis of epithelial tissues and progression of epithelial tumors.Targeted therapies in development for non-small cell lung cancerLinking changes in epithelial morphogenesis to cancer mutations using computational modelingAutophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumabStructural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 ProteinHER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitorsActivating HER2 mutations in HER2 gene amplification negative breast cancerAZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerTargeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumorsHER2 activating mutations are targets for colorectal cancer treatmentEGFR-TKI resistance in NSCLC patients: mechanisms and strategiesAST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivoCancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.HER2 somatic mutations are associated with poor survival in HER2-negative breast cancersAn adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.The quest to overcome resistance to EGFR-targeted therapies in cancer.Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro systemWhole exome sequence analysis of serous borderline tumors of the ovary.Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies.MicroRNA and HER2-overexpressing cancer.Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain: a molecular dynamics study.Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.Current concepts on the molecular pathology of non-small cell lung carcinoma.Dysfunctions associated with methylation, microRNA expression and gene expression in lung cancerEGFR-mutated lung cancer: a paradigm of molecular oncology.Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses.The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
P2860
Q24313194-40B2FB22-6AD0-4D4A-BD16-9697FCC8738AQ24649935-D6BBCF92-594F-4993-8A17-D5F3C5DB3621Q26741814-8F60B324-E216-462B-84FC-070340F1B909Q26744339-72BAAF41-1809-4AF8-BB85-B9FBC7A6CFF6Q26781683-C40D2D78-3893-4771-9D09-ED3F440BD9A7Q26797471-F5767698-992E-4EA1-B6FE-9F8499C7BABBQ26798882-7B70D30A-3F96-4663-B900-A372A104ACACQ26801167-1E413C79-64A7-4F25-9ED5-8068B977DABBQ26824536-37C09AA4-A92C-4DD9-9EA5-9F37D70D8AFDQ26866534-BB9C5C13-1B1C-4B5F-A127-FBFDF090CE90Q27015094-88A80813-3203-4736-BF20-CCBBCE7034DFQ27022852-D7F8FE39-1849-47A9-AC87-ACE3E4E3DCF1Q27334632-B59C0AB4-150F-4741-BB7D-32169B608C72Q27346475-55FFF171-2A31-42C7-9D13-E39B26875915Q27667382-AE8E7318-E567-4ABE-A574-BC7227D6D6C9Q27851461-A7DF3EF1-702D-4708-97F8-61ED838514A4Q27851975-1F581C28-BB24-422A-9435-55ACEB41CE64Q27851987-F79DAE9D-7BA6-40DD-8D97-BAC8B9A309EEQ27853013-FEF090A0-C74C-4048-8C55-2C4071741CA2Q27853154-1FDEE104-2429-4D1E-BF7E-04D6AABCD889Q27853193-1E8A74FD-92CD-4E21-80CA-F9A8FF1F45D5Q28394310-E55ACC6D-CE5F-457C-BE28-5A87C8EEED20Q28479059-9917C001-BB41-4AB0-98EB-8F75E339FAF4Q33591140-8AED1D05-4F99-4E04-8D2F-D9A1C046E78EQ33601653-73786D1A-D5D8-47BC-B969-89D71BBD6E99Q33607579-049704CF-5A27-4AD4-911A-706814ADC3CCQ33699124-8FCA4DB4-1834-4FB5-952A-8A054F9200E6Q33725976-7A71F09B-6371-4FBD-A51F-05312AB9CF2BQ33747967-8BFFB4B3-7CED-4F28-91B0-5BB8A62B1637Q33853093-221E3A99-91A1-4EEA-8809-80EF3CA5B4E9Q33907971-5C62056D-1A3C-4A89-9B92-4D12FC56F667Q33994744-839AABEF-BFFF-4AF5-B75A-119AE000ABFFQ34010366-6A2E991A-F1A5-4DEF-903E-89F2CFDF14DBQ34028470-06763DBF-37BE-478D-8EB9-DD009CCBFF24Q34158153-2B7A1E7D-DBDD-4BE6-8868-9AB5E0530AE3Q34310062-F4C264E0-A32D-415B-A724-AD00E184892BQ34389624-E8FF59B1-EBC5-4CA4-887F-A5231C8BFCD6Q34406334-15A33976-1A5C-4B62-9BC0-FDED66C89204Q34442958-825D3C08-AA04-4FE2-B1E5-46F1B00E8743Q34493341-3DEE5D5D-F691-4535-B75F-50B02507801F
P2860
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
HER2 kinase domain mutation re ...... GFR tyrosine kinase inhibitors
@ast
HER2 kinase domain mutation re ...... GFR tyrosine kinase inhibitors
@en
HER2 kinase domain mutation re ...... GFR tyrosine kinase inhibitors
@en-gb
HER2 kinase domain mutation re ...... GFR tyrosine kinase inhibitors
@nl
type
label
HER2 kinase domain mutation re ...... GFR tyrosine kinase inhibitors
@ast
HER2 kinase domain mutation re ...... GFR tyrosine kinase inhibitors
@en
HER2 kinase domain mutation re ...... GFR tyrosine kinase inhibitors
@en-gb
HER2 kinase domain mutation re ...... GFR tyrosine kinase inhibitors
@nl
prefLabel
HER2 kinase domain mutation re ...... GFR tyrosine kinase inhibitors
@ast
HER2 kinase domain mutation re ...... GFR tyrosine kinase inhibitors
@en
HER2 kinase domain mutation re ...... GFR tyrosine kinase inhibitors
@en-gb
HER2 kinase domain mutation re ...... GFR tyrosine kinase inhibitors
@nl
P2093
P921
P3181
P1433
P1476
HER2 kinase domain mutation re ...... GFR tyrosine kinase inhibitors
@en
P2093
Adi F Gazdar
Archana Narasanna
Carlos L Arteaga
Frederick Y Wu
Graham Carpenter
Marianela Perez-Torres
Senthil K Muthuswamy
Seungchan Yang
Shizhen Emily Wang
P3181
P356
10.1016/J.CCR.2006.05.023
P407
P577
2006-07-01T00:00:00Z